ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Safety and Efficacy of Imlifidase in Highly-Sensitized Kidney Transplant Patients: Results from a Phase 2 Study

S. C. Jordan1, C. Legendre2, N. Desai3, T. Lorant4, M. Bengtsson4, L. Laxmyr5, B. Lonze6, A. Vo1, K. J. Wood7, C. Kjellman5, R. A. Montgomery6

1Cedars-Sinai Medical Center, Los Angeles, CA, 2Hopital Necker, Paris, France, 3Johns Hopkins University, Baltimore, MD, 4Uppsala University, Uppsala, Sweden, 5Hansa Medical AB, Lund, Sweden, 6NYU Langone Health Transplant Institute, New York, NY, 7University of Oxford, Oxford, United Kingdom

Meeting: 2019 American Transplant Congress

Abstract number: 29

Keywords: Highly-sensitized, Kidney transplantation

Session Information

Date: Sunday, June 2, 2019

Session Name: Concurrent Session: Kidney Immunosuppression: Desensitization

Session Time: 2:30pm-4:00pm

 Presentation Time: 3:06pm-3:18pm

Location: Ballroom A

Related Abstracts
  • Anti-HLA IgM Antibodies Are Reduced in Highly-HLA Sensitized Patients Transplanted after Imlifidase (IdeS) Treatment
  • Three-Year Outcomes of Highly-Sensitized Kidney Transplant Recipients Desensitized with Imlifidase (IdeS)

*Purpose: Many patients eligible for kidney transplantation are sensitized to allo-HLA antigens and face prolonged waiting times and increased mortality. The presence of donor specific antibody (DSA) portends inferior allograft survival. Currently available desensitization strategies have variable effectiveness and side effects. Imlifidase is an enzyme that rapidly cleaves human IgG antibodies and is being evaluated in sensitized patients with a low likelihood of receiving a compatible kidney by any other available modalities.

*Methods: This single arm, 6-month, open label trial assessed imlifidase in abrogating a positive crossmatch (CXM) following drug delivery, enabling renal transplantation. The primary end-point was conversion of a positive to a negative CXM (CDC or Flow Cytometry) to either a living or deceased donor kidney.

*Results: 18 patients were enrolled with a median calculated PRA of 99.6% and a mean fluorescence intensity [MFI] >2000. All patients had a positive CXM to their donor and half with an immunodominant DSA >12000 MFI. Following imlifidase infusion 17/18 patients converted to a negative CXM; 1 was borderline FCXM positive and virtual CXM negative. At end of study, patient survival was 100%, graft survival was 89% (figure); the median eGFR was 50 (95% CI 36-61). There were 2 graft losses due to primary nonfunction; 25% of patients had biopsy-proven antibody mediated rejection (AMR). All AMRs were effectively treated using standard of care therapy. There were no treatment-related safety concerns.

*Conclusions: Imlifidase, which was well tolerated, enabled all patients to undergo transplantation resulting in good kidney function and graft survival. Frequency of AMR was at a similar level as previously reported for highly sensitized patients undergoing other desensitization protocols. Most AMR episodes were attributable to DSA rebound which generally occurs 7-10 days after imlifidase treatment. Imlifidase is a promising new agent that may enable kidney transplantation for highly sensitized patients, who would otherwise have no hope for a lifesaving transplant.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Jordan SC, Legendre C, Desai N, Lorant T, Bengtsson M, Laxmyr L, Lonze B, Vo A, Wood KJ, Kjellman C, Montgomery RA. Safety and Efficacy of Imlifidase in Highly-Sensitized Kidney Transplant Patients: Results from a Phase 2 Study [abstract]. Am J Transplant. 2019; 19 (suppl 3). https://atcmeetingabstracts.com/abstract/safety-and-efficacy-of-imlifidase-in-highly-sensitized-kidney-transplant-patients-results-from-a-phase-2-study/. Accessed January 27, 2021.

« Back to 2019 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    This site uses cookies: Find out more.